NDA 021802 · Sandoz
Focalin Xr
Dexmethylphenidate Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
May 26, 2005
Approved uses
4
Original approval plus efficacy supplements
Registered trials
33
11 Phase 3, 3 recruiting
FAERS reports
4,283
1,583 serious, 36 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION Dexmethylphenidate hydrochloride extended-release capsules has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dexmethylphenidate hydrochloride extended-release capsules, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing dexmethylphenidate hydrochloride extended-release capsules, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dexmethylphenidate hydrochloride extended-release capsules treatment, reassess each patient’s risk of abuse, misuse,...
What it is approved for
From the label in effect Apr 30, 2026.
Dexmethylphenidate hydrochloride extended-release capsules is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies ( 14 )]. Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 )]. Dexmethylphenidate hydrochloride extended-release capsules is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) ( 1 ). Limitations of Use The use of dexmethylphenidate hydrochloride extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.7 , 8.4 ).
Mechanism: Dexmethylphenidate hydrochloride is a CNS stimulant. The mode of therapeutic action in ADHD is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 23, 2009 Supplement 14 · Efficacy LetterLabel
- Oct 17, 2008 Supplement 12 · Efficacy Letter
- Apr 11, 2006 Supplement 1 · Efficacy LetterLabel
- May 26, 2005 Original approval · Type 3 - New Dosage Form Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
8 products under this application
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 35MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 30MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 20MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 40MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 15MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FOCALIN XR · DEXMETHYLPHENIDATE HYDROCHLORIDE 10MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dexmethylphenidate" as an intervention, any sponsor and status, largest first.
- Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01074294 · 740 participants · Start Mar 16, 2010 · Primary completion Jun 20, 2011
Drug: OPDC-34712; Placebo and 1 more · For: Attention Deficit Hyperactivity Disorder
Sites: Little Rock, Arkansas; Beverly Hills, California; Irvine, California · 35 sites in all
- AWARE: Management of ADHD in Autism Spectrum DisorderPivotal-lookingRecruiting
Daniel CouryAcademic, hospital or other
NCT05916339 · 500 participants (planned) · Start Oct 1, 2023 · Primary completion Jan 1, 2027
Drug: Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication; Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant. · For: ADHD; Autism Spectrum Disorder
Sites: Irvine, California; Los Angeles, California; Portland, Maine · 13 sites in all
- Treating Young Children With Attention Deficit Hyperactivity DisorderPivotal-lookingRecruiting
Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
NCT07300956 · 370 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 2030
Drug: Guanfacine (GUA); Methylphenidate (MPH) · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Palo Alto, California; Boston, Massachusetts; Kansas City, Missouri · 5 sites in all
- KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHDPivotal-lookingCompleted
Zevra TherapeuticsIndustry
NCT03460652 · 282 participants · Start Mar 13, 2018 · Primary completion Jun 20, 2019
Drug: KP415 oral capsule · For: ADHD
Sites: Little Rock, Arkansas; Colorado Springs, Colorado; Bradenton, Florida · 19 sites in all
- Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity DisorderPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00301236 · 252 participants · Start Feb 2006
Drug: Dexmethylphenidate HCl extended-release capsules · For: ADHD, ADD
Sites: Mesa, Arizona; Little Rock, Arkansas; Los Angeles, California · 25 sites in all
- An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHDPivotal-lookingCompleted
Corium, Inc.Industry
NCT05685732 · 246 participants · Start Mar 22, 2023 · Primary completion May 2, 2024
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) · For: Attention Deficit/Hyperactivity Disorder
Sites: Little Rock, Arkansas; Anaheim, California; Centennial, Colorado · 20 sites in all
- Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity DisorderPivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00429273 · 212 participants · Start Jan 2007 · Primary completion Jul 2011
Drug: Guanfacine; Methylphenidate (MPH) · For: Attention Deficit Disorder With Hyperactivity
Sites: Los Angeles, California
- Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00776009 · 165 participants · Start Oct 2008 · Primary completion Dec 2008
Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR); Placebo · For: Attention-Deficit/Hyperactivity Disorder (ADHD)
Sites: Little Rock, Arkansas; Bradenton, Florida; South Miami, Florida · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective769
- nausea206
- anxiety199
- headache188
- fatigue176
- abnormal behaviour168
- feeling abnormal167
- decreased appetite160
- disturbance in attention158
- off label use150
- insomnia147
- aggression144
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 31 |
| 2006 | 78 |
| 2007 | 82 |
| 2008 | 82 |
| 2009 | 83 |
| 2010 | 82 |
| 2011 | 114 |
| 2012 | 125 |
| 2013 | 116 |
| 2014 | 149 |
| 2015 | 394 |
| 2016 | 420 |
| 2017 | 313 |
| 2018 | 245 |
| 2019 | 277 |
| 2020 | 242 |
| 2021 | 177 |
| 2022 | 244 |
| 2023 | 303 |
| 2024 | 263 |
| 2025 | 258 |
| 2026 | 191 |
Recalls
1 FDA enforcement reports for this application.
Jun 1, 2026 · Class III · Ongoing
Labeling: Incorrect or Missing Lot and/or Exp Date
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Focalin XR (Dexmethylphenidate HCl)
2024 spending
$1.1M
Beneficiaries
939
3,848 claims
Per beneficiary
$1,133
$7.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,211,978 |
| 2021 | $1,234,967 |
| 2022 | $1,362,688 |
| 2023 | $1,884,658 |
| 2024 | $1,063,615 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.
Childress AC, Marraffino A, Cutler AJ, et al. · J Child Adolesc Psychopharmacol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
Kollins SH, Braeckman R, Guenther S, et al. · J Child Adolesc Psychopharmacol 2021 · Randomized Controlled Trial
- Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder.
Fainberg G, Leitner Y, Zur D, et al. · J Child Adolesc Psychopharmacol 2022 · Clinical Trial
- Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.
Zhu HJ, Patrick KS, Straughn AB, et al. · J Clin Psychopharmacol 2017 · Randomized Controlled Trial
- Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.
Stein MA, Waldman I, Newcorn J, et al. · J Child Adolesc Psychopharmacol 2014 · Comparative Study, Randomized Controlled Trial
- Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
Spencer TJ, Adler LA, McGough JJ, et al. · Biol Psychiatry 2007 · Multicenter Study, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.